X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Piramal Healthcare with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs DIVIS LABORATORIES - Comparison Results

PIRAMAL ENTERPRISES    Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES DIVIS LABORATORIES PIRAMAL ENTERPRISES/
DIVIS LABORATORIES
 
P/E (TTM) x 9.1 31.9 28.6% View Chart
P/BV x 3.0 5.2 58.3% View Chart
Dividend Yield % 0.8 1.0 84.3%  

Financials

 PIRAMAL ENTERPRISES   DIVIS LABORATORIES
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-17
DIVIS LABORATORIES
Mar-17
PIRAMAL ENTERPRISES/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2,0951,222 171.4%   
Low Rs1,025784 130.7%   
Sales per share (Unadj.) Rs492.8153.1 321.9%  
Earnings per share (Unadj.) Rs72.639.9 181.6%  
Cash flow per share (Unadj.) Rs94.744.6 212.3%  
Dividends per share (Unadj.) Rs21.0010.00 210.0%  
Dividend yield (eoy) %1.31.0 135.0%  
Book value per share (Unadj.) Rs862.5201.8 427.4%  
Shares outstanding (eoy) m172.56265.47 65.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.26.6 48.3%   
Avg P/E ratio x21.525.1 85.6%  
P/CF ratio (eoy) x16.522.5 73.3%  
Price / Book Value ratio x1.85.0 36.4%  
Dividend payout %28.925.0 115.6%   
Avg Mkt Cap Rs m269,194266,266 101.1%   
No. of employees `0004.09.7 41.2%   
Total wages/salary Rs m17,9394,687 382.7%   
Avg. sales/employee Rs Th21,190.34,175.0 507.6%   
Avg. wages/employee Rs Th4,470.1481.5 928.4%   
Avg. net profit/employee Rs Th3,120.01,089.3 286.4%   
INCOME DATA
Net Sales Rs m85,03740,643 209.2%  
Other income Rs m2,338749 312.1%   
Total revenues Rs m87,37441,392 211.1%   
Gross profit Rs m34,99114,460 242.0%  
Depreciation Rs m3,8171,233 309.5%   
Interest Rs m20,31023 89,866.4%   
Profit before tax Rs m13,20213,953 94.6%   
Minority Interest Rs m1,6990-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1000-   
Tax Rs m2,2813,349 68.1%   
Profit after tax Rs m12,52010,604 118.1%  
Gross profit margin %41.135.6 115.7%  
Effective tax rate %17.324.0 72.0%   
Net profit margin %14.726.1 56.4%  
BALANCE SHEET DATA
Current assets Rs m87,59040,105 218.4%   
Current liabilities Rs m185,5786,595 2,814.1%   
Net working cap to sales %-115.282.5 -139.8%  
Current ratio x0.56.1 7.8%  
Inventory Days Days31119 26.2%  
Debtors Days Days4881 58.9%  
Net fixed assets Rs m108,52319,995 542.8%   
Share capital Rs m345531 65.0%   
"Free" reserves Rs m148,48153,043 279.9%   
Net worth Rs m148,82653,574 277.8%   
Long term debt Rs m144,9570-   
Total assets Rs m482,39461,585 783.3%  
Interest coverage x1.7618.4 0.3%   
Debt to equity ratio x1.00-  
Sales to assets ratio x0.20.7 26.7%   
Return on assets %6.817.3 39.4%  
Return on equity %8.419.8 42.5%  
Return on capital %12.026.1 45.8%  
Exports to sales %00-   
Imports to sales %025.2 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA10,259 0.0%   
Fx inflow Rs m15,00135,384 42.4%   
Fx outflow Rs m5,15010,399 49.5%   
Net fx Rs m9,85124,985 39.4%   
CASH FLOW
From Operations Rs m-100,39311,493 -873.5%  
From Investments Rs m-24,202-11,372 212.8%  
From Financial Activity Rs m135,705-93 -145,762.2%  
Net Cashflow Rs m11,11028 39,118.7%  

Share Holding

Indian Promoters % 52.9 52.0 101.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.0 11.8 33.9%  
FIIs % 26.6 19.0 140.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 17.2 95.9%  
Shareholders   93,274 31,796 293.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   ORCHID PHARMA LTD  CIPLA  ASTRAZENECA PHARMA  VENUS REMEDIES  STERLING BIOTECH  

Compare PIRAMAL ENTERPRISES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY18); Net Profit Up 1230.7%

May 30, 2018 | Updated on May 30, 2018

For the quarter ended March 2018, PIRAMAL ENTERPRISES has posted a net profit of Rs 39 bn (up 1230.7% YoY). Sales on the other hand came in at Rs 30 bn (up 21.5% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Jun 22, 2018 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS